Data on COVID-19 outcomes in Asian Americans and Pacific Islanders (AAPI) are lacking. We analyzed data from 6,244 patients from the COVID-19 and Cancer Consortium, including 6.0% AAPI patients, to examine disparities in outcomes following acute COVID-19. Despite AAPI patients having lower median BMI than non-Hispanic White (NHW) patients and higher diabetes rates, both groups showed similar 30-day mortality and COVID-19 outcomes. In multivariable analyses, morbid obesity (BMI >35 kg/m2) in AAPI patients was associated with significantly higher 30-day mortality (OR 4.96; 95% CI 1.78 – 13.88) and COVID-19 severity (OR 2.6; 95% CI 1.26 – 5.35); underscoring the differential impact of obesity in AAPI patients.

The authors have declared no competing interest.

REDCap is developed and supported by the Vanderbilt Institute for Clinical and Translational Research (grant UL1 TR000445 from the National Center for Advancing Translational Sciences, National Institutes of Health). This work was supported in part by Henry Ford Cancer Institute. RHN is a Recipient of the Robert A. Winn Diversity in Clinical Trials Career Development Award, funded by Bristol Myers Squibb Foundation. This study was partly supported by grants from the American Cancer Society and Hope Foundation for Cancer Research (No. MRSG-16-152-01 -CCE to DPS); the National Cancer Institute (grant number P30CA054174 to DPS and PKS); the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2 TR002646 to PKS. This study was partly supported by grants from the National Cancer Institute [grant number P30 CA068485 to Vanderbilt University Medical Center. The funding sources had no role in the writing of the manuscript of the decision to submit it for publication.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study (NCT04354701) was approved by the Vanderbilt University Medical Center institutional review board and participating sites.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

↵† Co-first authors

↵‡ Co-last authors

Research support: REDCap is developed and supported by the Vanderbilt Institute for Clinical and Translational Research (grant UL1 TR000445 from the National Center for Advancing Translational Sciences, National Institutes of Health). This work was supported in part by Henry Ford Cancer Institute. RHN is a Recipient of the Robert A. Winn Diversity in Clinical Trials Career Development Award, funded by Bristol Myers Squibb Foundation. This study was partly supported by grants from the American Cancer Society and Hope Foundation for Cancer Research (No. MRSG-16-152-01 -CCE to DPS); the National Cancer Institute (grant number P30CA054174 to DPS and PKS); the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2 TR002646 to PKS. This study was partly supported by grants from the National Cancer Institute [grant number P30 CA068485 to Vanderbilt University Medical Center. The funding sources had no role in the writing of the manuscript of the decision to submit it for publication.

Competing Interests The authors declare no competing financial interests.